This webcast is not certified for credit

Release Date: October 1, 2021
Expiration Date: September 30, 2022

Target Audience
This activity is intended for community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with MM.

Learning Objectives
Upon completion of this activity learners should be able to:

• Incorporate minimal residual disease assessment when evaluating prognosis and potential relapse
• Evaluate treatment approaches for patients with relapsed and/or refractory MM, specifically the decision to include a monoclonal antibody, bispecific antibody, or antibody-drug conjugate, CAR T cell therapy, and combination with other agents for triplet therapy
• Develop strategies to mitigate treatment-related adverse events that may occur during the care of patients with RRMM
•  Discuss the results of clinical trials that are investigating emerging novel agents in patients with RRMM

Method of Participation
There are no fees for participating in this activity

Faculty and Planning Committee Disclosures

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planner and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education.  Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.  All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

Faculty
Sagar Lonial, MD, FACP
Consulting Fees: Amgen Inc., Bristol-Myers Squibb Company, Bluebird, Celgene Corporation, Genentech, Novartis, Sanofi, Takeda Oncology
Other: Board of directors TG Therapeutics with stock

Thomas Martin, MD
Consultant Fees: GlaxoSmithKline LLC, 
Research Funding to Institution: Amgen Inc, Janssen Oncology, Sanofi

Krina Patel, MD, MSc
Consulting Fees: Bristol Myers Squibb, Celgene Corporation, Cellectis, Janssen Oncology, Nektar Therapeutics, Pfizer Inc., Poseida Therapeutics, Inc., Precision BioSciences

Contracted Research & Publishing: AbbVie Inc., Bristol Myers Squibb, Celgene Corporation, Cellectis, Janssen Oncology, Nektar Therapeutics, Poseida Therapeutics, Inc., Precision BioSciences

Planning Committee
The following planning committee members have nothing to disclose:

UNMC: Brenda Ram, CMP, CHCP
Bio Ascend: Chloe Dunnam; Dru Dace, PhD; Kraig Steubing

Support
This activity is supported by educational grants from Bristol Myers Squibb and Oncopeptides, Inc.

Technical Requirements
This activity is best experienced using the most current browser (or one back) of Firefox, Chrome, Safari, Internet Explorer, or Microsoft Edge. For all activities featuring audio you must have a sound card and speakers. To view graphic images and references that appear in separate "pop-up" windows, you must have JavaScript and session cookies enabled on your computer. Adobe Acrobat Reader may be required for certain activities.

Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.